Results 81 to 90 of about 244,342 (370)

BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells

open access: yesCell Death and Disease, 2020
The anti-apoptotic BCL-2 proteins (BCL-2, BCL-XL, MCL-1, A1, BCL-W) counteract apoptotic signals emerging during development and under stress conditions, and are thus essential for the survival of every cell. While the “BCL-2 addiction” of different cell
S. Afreen   +8 more
semanticscholar   +1 more source

High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia. [PDF]

open access: yes, 2016
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a predictive biomarker of disease progression in many malignancies, including imatinib-treated chronic myeloid leukemia (CML).
Butterworth, M.   +7 more
core   +1 more source

BCL-xL, a Mitochondrial Protein Involved in Successful Aging: From C. elegans to Human Centenarians. [PDF]

open access: yes, 2020
B-Cell Lymphoma-extra-large (BCL-xL) is involved in longevity and successful aging, which indicates a role for BCL-xL in cell survival pathway regulation. Beyond its well described role as an inhibitor of apoptosis by preventing cytochrome c release, BCL-
Borrás, Consuelo   +7 more
core   +1 more source

Praf2 is a novel Bcl-xL/Bcl-2 interacting protein with the ability to modulate survival of cancer cells.

open access: yesPLoS ONE, 2010
Increased expression of Bcl-xL in cancer has been shown to confer resistance to a broad range of apoptotic stimuli and to modulate a number of other aspects of cellular physiology, including energy metabolism, cell cycle, autophagy, mitochondrial fission/
Maria Teresa Vento   +6 more
doaj   +1 more source

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival

open access: yesCell Death and Disease, 2019
Malignant melanoma is one of the most difficult cancers to treat due to its resistance to chemotherapy. Despite recent successes with BRAF inhibitors and immune checkpoint inhibitors, many patients do not respond or become resistant to these drugs. Hence,
Erinna F. Lee   +23 more
semanticscholar   +1 more source

Bad expression influences time to androgen escape in prostate cancer [PDF]

open access: yes, 2007
<b>OBJECTIVE</b>: To assess the role of selected downstream Bcl-2 family members (Bad, Bax, Bcl-2 and Bcl-xL) in the development of androgen-independent prostate cancer (AIPC), as androgen-deprivation therapy is the treatment of choice in ...
Bracarda S   +9 more
core   +1 more source

Trans-1,3-diphenyl-2,3-epoxypropan-1-one, a chalcone derivative, induces apoptosis via ROS-mediated down-regulation of Bcl-xL in human leukemia HL-60 cells [PDF]

open access: yes, 2015
The anticancer effects of trans-1,3-diphenyl-2,3-epoxypropan-1-one (DPEP), a chalcone derivative, were investigated in human leukemia HL-60 cells. Treatment of HL-60 cells with various concentration of DPEP resulted in a sequence of events characteristic
Ahn, Ginnae   +10 more
core   +1 more source

Molecular basis for the interplay of apoptosis and proliferation mediated by Bcl-xL:Bim interactions in pancreatic cancer cells [PDF]

open access: yes, 2012
A major mechanism through which cancer cells avoid apoptosis is by promoting the association of anti-apoptotic members of the pro-survival Bcl-2 protein family (like Bcl-2 and Bcl-xL) with BH3 domain-only proteins (like Bim and Bid).
Abrol, Ravinder   +3 more
core   +1 more source

Beyond cell death - antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro. [PDF]

open access: yesPLoS ONE, 2013
Migration and invasion of malignant cells are prerequisites for cancer progression and metastasis. The Bcl-2 family of proteins consists of about 25 members and has been extensively studied in the context of apoptosis.
Bruno Christian Koehler   +9 more
doaj   +1 more source

Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells

open access: yesHaematologica, 2023
BCL-XL and BCL-2 are key anti-apoptotic proteins and validated cancer targets. 753B is a novel BCL-XL/BCL-2 proteolysis targeting chimera (PROTAC) that targets both BCL-XL and BCL-2 to the von Hippel-Lindau (VHL) E3 ligase, leading to BCLX L/BCL-2 ...
Yannan Jia   +19 more
doaj   +1 more source

Home - About - Disclaimer - Privacy